KYBORA is pleased to announce the partnering of berisporocin in China

KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.

3 2 月, 2023

No comments

News

https://www.daewoong.co.kr/en/prcenter/newsview?pageIndex=1&idx=2564&no=369&srchword=Bersiporocin is a prolyl-tRNA synthetase inhibitor being developed by Daewoong for IPF and potentially other fibrotic indications.
KYBORA developed a comprehensive analysis of the commercial potential of Bersiporocin in Greater China, giving Daewoong a powerful tool to support its licensing discussions.
The agreement demonstrates KYBORA’s ability to help its clients strike lucrative cross border deals and maximize the value of their products globally.
Deal press release can be accessed here https://www.daewoong.co.kr/en/prcenter/newsview?pageIndex=1&idx=2564&no=369&srchword=e.

TAGS:#biopharma Licensing